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Abstract:
Temporal organisation of molecular and physiological processes is driven 
by environmental and behavioural cycles, as well as by self-sustained 
molecular circadian oscillators. Quantification of phase, amplitude, 
period, and disruption of circadian rhythms is essential for understanding 
their contribution to sleep-wake disorders, social jet-lag, inter-individual 
differences in entrainment and the development of chrono-therapeutics. 
  
Traditionally, assessment of the human circadian system, and the output 
of the SCN in particular, required collection of long time series of 
univariate markers such as melatonin or core body temperature. Data 
were collected in specialised laboratory protocols designed to control for 
environmental and behavioural influences on rhythmicity. These 
protocols are time-consuming, expensive, and are not practical for 
assessing circadian status in patients or in participants in epidemiologic 
studies.   
Novel approaches for assessment of circadian parameters of the SCN or 
peripheral oscillators have been developed. They are based on machine 
learning or mathematical model-informed analyses of features extracted 
from one or a few samples of high dimensional data such as 
transcriptomes, metabolomes, long term simultaneous recording of 
activity, light exposure, skin temperature, and heart rate, or in vitro 
approaches. Here, we review whether these approaches successfully 
quantify parameters of central and peripheral circadian oscillators as 
indexed by gold standard markers. While several approaches perform 
well under entrained conditions when sleep occurs at night, the methods 
either perform worse in other conditions such as shift work, or they have 
not been assessed under any conditions other than entrainment and thus 
we do not yet know how robust they are. 
Novel approaches for the assessment of circadian parameters hold 
promise for circadian medicine, chrono-therapeutics, and chrono-
epidemiology. There remains a need to validate these approaches 
against gold standard markers, in individuals of all sexes and ages, in 
patient populations, and, in particular, under conditions in which 
behavioural cycles are displaced. 
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Abstract
Temporal organisation of molecular and physiological processes is driven by environmental and 
behavioural cycles, as well as by self-sustained molecular circadian oscillators. Quantification of 
phase, amplitude, period, and disruption of circadian rhythms is essential for understanding their 
contribution to sleep-wake disorders, social jet-lag, inter-individual differences in entrainment and 
the development of chrono-therapeutics.  
Traditionally, assessment of the human circadian system, and the output of the SCN in particular, 
required collection of long time series of univariate markers such as melatonin or core body 
temperature. Data were collected in specialised laboratory protocols designed to control for 
environmental and behavioural influences on rhythmicity. These protocols are time-consuming, 
expensive, and are not practical for assessing circadian status in patients or in participants in 
epidemiologic studies.  
Novel approaches for assessment of circadian parameters of the SCN or peripheral oscillators have 
been developed. They are based on machine learning or mathematical model-informed analyses of 
features extracted from one or a few samples of high dimensional data such as transcriptomes, 
metabolomes, long term simultaneous recording of activity, light exposure, skin temperature, and 
heart rate, or in vitro approaches. Here, we review whether these approaches successfully quantify 
parameters of central and peripheral circadian oscillators as indexed by gold standard markers. 
While several approaches perform well under entrained conditions when sleep occurs at night, the 
methods either perform worse in other conditions such as shift work, or they have not been 
assessed under any conditions other than entrainment and thus we do not yet know how robust 
they are. 
Novel approaches for the assessment of circadian parameters hold promise for circadian medicine, 
chrono-therapeutics, and chrono-epidemiology. There remains a need to validate these approaches 
against gold standard markers, in individuals of all sexes and ages, in patient populations, and, in 
particular, under conditions in which behavioural cycles are displaced. 
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Introduction
Assessing the phase, period, and amplitude of circadian oscillators is central to the study of circadian 
rhythms, be it in cyanobacteria, mice, or humans (Kuhlman et al., 2018). Accurate phase 
measurements enable description of the phase relationship (relative timing) of circadian oscillations 
with the environmental and behavioural cycles in the study of entrainment in humans (Duffy et al., 
1999) (Wright et al., 2005). Accurate phase assessments are also a prerequisite to describe the 
interrelations between circadian oscillators in any multi-oscillator system, be it hierarchically 
organised or not  (Honma, 2018) (Dijk and Lockley, 2002). Accurate assessments of period and 
amplitude enable identification of mechanisms underlying abnormal entrainment or lack of 
robustness in circadian regulation of physiological processes. Developing accurate and unobtrusive 
methods to assess period, phase, amplitude, robustness, and disruption is critical to understand the 
role of circadian rhythms in physical and mental health and their disorders. Traditional human 
circadian rhythm research areas include shift-work, jet lag, and circadian rhythm sleep-wake 
disorders (Sack et al., 2007a). More recently, phenomena like social-jet lag and applications like 
chrono-therapeutics and chrono-medicine have gained attention, and the epidemiology of circadian 
disruption is an emerging area of interest (Roenneberg and Merrow, 2016)]. Methods that can 
accurately assess circadian parameters and be implemented at scale and at low cost are critical for 
the translation of basic circadian rhythm research to all these areas (Cederroth et al., 2019) 
(Mullington et al., 2016) (Munch and Kramer, 2019). Recent years have seen the introduction of 
novel approaches to the assessment of circadian parameters and, in particular, circadian phase in 
humans. Some of these methodologies use machine learning approaches to extract features that 
predict circadian parameters from high dimensional ‘omics’ data, whereas others are based on 
multiple behavioural, environmental and physiological variables collected from research or 
consumer grade wearables, combinations of mathematical modelling and wearable-based data 
acquisition, or analyses of in vitro circadian behaviour in human cell cultures. Here we will revisit 
(Duffy and Dijk, 2002) some of the issues, pitfalls, and requirements for the assessment of circadian 
parameters in humans and discuss some of the novel approaches within that context. 
Diurnal rhythmicity, circadian rhythmicity, endogenous circadian components, behavioural 
masking
Rhythmicity may be observed in any physiological or behavioural variable and quantification of this 
rhythmicity may be of intrinsic interest. However, often rhythmicity is assessed not for its own sake, 
but to quantify characteristics of an underlying circadian oscillator, which is assumed to drive the 
rhythmicity being assessed. A central concept in circadian rhythm research is that an overt 24-h 
diurnal rhythm can only be considered a circadian rhythm when it persists in the absence of masking 
by external environmental and behavioural 24-h cycles (Kuhlman et al., 2018). Many laboratory 
experiments in which organisms, including humans, were studied while shielded from 24-h 
environmental cycles have demonstrated that at least part of overt rhythmicity is driven by 
endogenous circadian oscillators. However, those studies have also revealed that 24-h 
environmental and behavioural cycles also contribute to 24-h rhythmicity in many aspects of 
physiology. This distinction between diurnal rhythmicity (due to 24-h rhythms in the environment 
and in behaviour) and circadian rhythmicity (due to endogenous processes) is critical to take into 
account when developing and applying methods for the quantitative assessment of circadian 
rhythmicity. Unfortunately, this important distinction is often overlooked, and we believe it has 
hampered progress in developing novel methods for assessing circadian timing and in understanding 
the role of circadian oscillators in disease (Lyall et al., 2018). 
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In the context of the distinction between diurnal and circadian rhythmicity, human circadian rhythm 
researchers also make a distinction between endogenous circadian components of a rhythm and 
evoked components. This distinction relates to the concept of behavioural masking and implies that 
assessment of the endogenous circadian component of a rhythm not only requires that components 
driven (masked) by environmental cycles are removed, but also that components driven (masked) by 
behavioural cycles must be controlled (Rietveld et al., 1993). It has now become clear that 
behavioural and environmental masking extends to rhythmicity at the molecular level. Thus, 
rhythmicity in the brain and blood transcriptome is to a large extent driven by the timing of the 
sleep-wake cycle (Maret et al., 2007) (Hor et al., 2019) (Archer et al., 2014) (Archer and Oster, 2015) 
and is affected by insufficient sleep (Moller-Levet et al., 2013) (Laing et al., 2019b). Likewise, 
rhythmicity in the liver is to a large extent driven by feeding rhythms and influenced by light (Atger 
et al., 2015) (Greenwell et al., 2019;  Koronowski et al., 2019). Protocols such as the constant routine 
or forced desynchrony, which eliminate or distribute masking uniformly across the circadian cycle, 
were developed to control this behavioural masking so that aspects of rhythmicity driven ‘directly’ 
by circadian clocks could be quantified. These protocols have been used primarily in human studies 
and the confounding effects of behavioural cycles, and the rest-activity cycle in particular, have 
often been ignored in animal studies. 
Novel circadian biomarkers must be robust to altered environmental and behavioural influences for 
them to be useful in patients with circadian rhythm disorders, in people who do shift work or have 
recently travelled to another time zone, and in individuals with social jet lag or who keep irregular 
sleep schedules. Therefore, in our evaluation of novel methods to quantify circadian rhythmicity, we 
consider the extent to which they can distinguish between environmental, behavioural, or 
endogenous circadian components of overt rhythmicity.
A biomarker for circadian phase, amplitude, and period of which oscillator?
Now that it has been established that circadian oscillators are present in every tissue, organ, and 
cell, it is more important than ever to be explicit about the circadian oscillator of interest when 
assessing a rhythmic output  (Mohawk et al., 2012) (Mure et al., 2018)[Fig 1]. Traditionally, and 
particularly so in research on circadian rhythm sleep-wake disorders, there has been a focus on 
assessing parameters of the ‘master circadian pacemaker’ located in the SCN  (Sack et al., 2007a) 
(Sack et al., 2007b). Obviously, there is more to the human circadian system than the SCN. 
Cardiologists may be interested in the phase, period, or amplitude of circadian oscillators in the 
heart (Thosar et al., 2018), or how the timing of anti-hypertensives impact blood pressure control 
(Smolensky et al., 2017); clinicians or researchers of metabolism may want to assess circadian 
parameters in the pancreas or adipocytes (Qian and Scheer, 2016). In fact, insulin sensitivity 
rhythms, glucose rhythms, and many other rhythms related to metabolism have already been 
characterised in humans (Poggiogalle et al., 2018). Immunologists may be interested in the extent to 
which the various white blood cell types vary across the diurnal cycle (Pick et al., 2019), how 
molecular processes related to immune function oscillate within each of these cell types, and how 
far these intracellular or intercellular rhythms are directly modulated by local circadian clocks 
(Baxter and Ray, 2019) (Downton et al., 2019). Oncologists are interested in rhythmicity in tumours 
and how circadian phase assessment may allow the most effective timing of chemo- or radio-
therapies (Shafi and Knudsen, 2019) (Shuboni-Mulligan et al., 2019). Neurologists and psychiatrists 
are interested in circadian rhythms in mood, seizures, and neurodegeneration (Logan and McClung, 
2019) (Khan et al., 2018;  Leng et al., 2019) (Pavlova et al., 2009) (Lucey et al., 2017). Whether these 
rhythms in heart rate, glucose, insulin sensitivity or leukocytes are driven by local tissue clocks 
and/or through central control from the SCN, and to what extent these rhythms reflect 
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‘endogenous’ circadian rhythms, or diurnal rhythmicity, or instead are driven by rhythmic 
behaviours, is not easily established. Nevertheless, novel methods and biomarkers to quantify 
rhythmicity and biomarkers may facilitate the characterisation of tissue-specific local oscillators, 
allowing for increased understanding of many normal and pathological physiological processes and 
the application of chronotherapies targeting specific organs and tissues. 
Standard parameters of circadian oscillators and the rhythms they generate are phase and intrinsic 
period, but aspects such as amplitude and waveform of rhythms can also be used to characterise 
rhythms, although the latter two are rarely assessed.   
Traditional peripheral markers for SCN phase and period 
The SCN drives many daily rhythms, including those observed in the autonomic nervous system  
(Buijs et al., 2013), endocrine rhythms(Czeisler and Klerman, 1999) (Morris et al., 2012), and in 
particular the circadian component of the sleep propensity rhythm (Dijk and Czeisler, 1995). The 
desire to assess characteristics of the circadian pacemaker located in the SCN arose from hypotheses 
predicting that changes in endogenous circadian parameters were the cause of changes in sleep 
timing, such as observed in ageing, circadian rhythm sleep-wake disorders, or between chronotypes 
(Sack et al., 2007b). Diagnosis and understanding of the aetiology of circadian rhythm sleep-wake 
disorders may be informed by accurate assessment of the SCN’s intrinsic period, amplitude, and/or 
phase. This desire to know about the status of the SCN pacemaker is also driven by the recognition 
that effects of sleep-wake therapeutics, be it light treatment or melatonin administration, are 
dependent on the circadian phase at which they are administered  (Duffy and Wright, 2005) (Keijzer 
et al., 2014). Effective timing of chrono-therapies aiming to correct SCN driven rhythms requires 
accurate assessment of the SCN phase to know when they should be applied to obtain the desired 
results. 
Because the SCN is not directly accessible in humans, the timing of peripheral markers is used as a 
proxy for SCN phase. The choice of which marker(s) to use is influenced by the ease of assessment, 
cost, and reliability of the marker itself. While sleep-wake propensity is influenced by the circadian 
system, the timing of the sleep-wake cycle is not considered a reliable marker of SCN phase or 
period in humans (Czeisler et al., 1999).Even though the circadian (SCN) phase at which sleep occurs 
impacts the duration and structure of sleep, studies of shift-workers and jet-lagged travellers as well 
as laboratory studies of spontaneous and forced desynchrony have demonstrated that sleep can 
occur at many phases and that the relationship between the timing of the sleep-wake cycle and SCN 
phase varies across conditions and both between and within individuals  (Dijk and Lockley, 2002).
Peripheral rhythms such as the core body temperature, cortisol, and melatonin rhythms have been 
used extensively as markers for circadian phase of the SCN. Several lines of evidence support the 
validity of these peripheral markers for SCN phase. Neuroanatomical tracer and lesion studies show 
that through its projections to the PVN and other hypothalamic nuclei, the SCN drives rhythmicity in 
melatonin and cortisol as well as core body temperature (Moore, 2013) . Further evidence comes 
from the observation that exposure to light induces equivalent phase shifts in these phase markers 
(Czeisler et al., 1990), and the sleep-propensity rhythm is closely coupled to the core body 
temperature and melatonin rhythms (Dijk et al., 1997). Reductions in amplitude induced by light 
pulses or phase shifts of the light-dark and sleep-wake cycle are correlated across melatonin, 
cortisol, and core body temperature  (Dijk et al., 2012) (Czeisler et al., 1990). 
Given the validity of these phase markers, assessing the phase of the SCN relative to clock time or to 
the external light-dark cycle, or even relative to another oscillator, would seem to be 
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straightforward. However, the key pitfall in using these phase markers remains that their overt 
rhythmicity is composed of both ‘endogenous’ circadian components and ‘evoked’ components. In 
humans, the plasma melatonin rhythm serves as an example of this. In constant darkness, a 
prominent rhythm of melatonin concentration in blood or saliva can be observed, with high values 
during the biological (subjective) night and low values during the biological (subjective) day. 
However, light has long been known to suppress melatonin. While initially it was thought that only 
bright light could do so, it is now recognized that light intensities as low as 6 lux can acutely suppress 
melatonin by 50% in some participants, thereby ‘masking’ the endogenous SCN phase and amplitude 
(Phillips et al., 2019) (Zeitzer et al., 2000)[Fig 2D]. Therefore, accurate estimation of the phase of the 
melatonin rhythm requires a time series of blood or saliva samples to be collected in very dim light  
(Benloucif et al., 2008), a requirement which is not easily met in the real world. The cortisol rhythm, 
besides being affected by light (Rahman et al., 2019), is also masked by stress and fasting, but just 
like melatonin, is little affected by sleep (Oster et al., 2017) [Fig 2B].  
Whereas in the case of melatonin the primary confounding variable is environmental (i.e. light), for 
other markers of SCN phase the primary confounding variables are behavioural. Core body 
temperature (CBT) is lower at night than during the day. The amplitude and phase of the observed 
CBT rhythm is very much influenced by the timing of rest/sleep. This is demonstrated by data 
showing that when sleep occurs at night the amplitude of the temperature rhythm is high, whereas 
when sleep occurs during the day the amplitude of the rhythm is greatly reduced [Fig 2A]. In fact, 
this masking can be so extreme as to cause an observed temperature nadir to occur during the day, 
even though the true endogenous nadir (revealed under appropriate conditions) is located at night. 
The masking impact of sleep on core temperature is due to a combination of supine posture, 
inactivity, and sleep itself (Krauchi and Deboer, 2010).  The difficulty of assessing circadian phase on 
the basis of temperature may be further illustrated by contrasting core temperature and skin 
temperature: whereas sleep lowers core temperature, skin temperature rises when we lie down and 
fall asleep, and the pattern of temperature varies across distal and proximal parts of the body 
(Krauchi et al., 2000) (Krauchi and Wirz-Justice, 1994). The conditions in which assessment of SCN 
phase is of most interest are also conditions in which this assessment is most challenging. In shift-
work and jet-lag, sleep will often be displaced from the normal circadian phase and/or normal clock 
time. Altered phase relationships between sleep and SCN phase also occur in Circadian Rhythm 
Sleep-Wake Disorders (CRSWD), social jet lag,  and neurodegeneration (Rahman et al., 2009). 
Furthermore, the sleep-wake cycle is almost always associated with cycles of dark-light and fasting-
feeding, and these latter cycles also affect physiological, endocrine, and molecular rhythms. Thus, 
these peripheral markers (melatonin, cortisol, core temperature) can only be used to assess SCN 
status when the masking effects of environmental and behavioural cycles are adequately controlled. 
For the same reasons, adequate environmental and behavioural control should be a prerequisite in 
the search for any novel methods to assess SCN status.
Univariate markers such as melatonin, cortisol, or core temperature can only be used as markers of 
the SCN status by collection of a timeseries. The timeseries should be sufficiently long to identify the 
phase, i.e. minimum, maximum, onset or offset, of the variable under study. If amplitude of the 
central clock is of interest, the time series must be at least a full circadian cycle (24 hours). In the 
search for novel methods to assess SCN status, a minimum duration timeseries of at least 24 hours 
should be used. 
In summary, peripheral univariate markers can be used to assess circadian parameters such as phase 
and amplitude, but require carefully controlled conditions, costly and labour-intensive protocols, 
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with repeated sampling of blood, urine, or saliva over extended periods of time, and are often 
burdensome for the research participant.
The dim light melatonin onset (DLMO) (Lewy et al., 1999) assessed in blood or saliva has emerged as 
the gold standard marker of choice, but urinary 6-sulphatoxy melatonin has also been used 
successfully  (e.g. (Lockley et al., 2015), although the duration of collection is longer and the 
temporal resolution of the phase assessment may be lower than for the DLMO.
Dim-light melatonin onset as a biomarker for SCN phase
The term biomarker is frequently used in medicine and clinical trials and is defined as “a 
characteristic that is objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention” 
(Menetski et al., 2019).  Some of the required or desirable characteristics of a biomarker are that it is 
present in easily accessible tissues or fluids; that it can be reliably quantified through established 
essays; that it is sensitive, specific, and valid in a wide variety of situations (robustness) and 
populations. The dim light melatonin onset (DLMO) is essentially a biomarker for SCN phase, and the 
DLMO meets many biomarker requirements. Importantly, even though melatonin is masked by light, 
the masking effects of the sleep-wake cycle itself on melatonin are small. This implies that melatonin 
is a robust marker for central circadian phase in those conditions in which the phase relationship 
between sleep and SCN may be changed.
Even though the DLMO is considered a gold standard, assessment of it is not without error. This 
maybe simple measurement error such as assay errors or errors related to imperfect 
implementation of the dim light protocol. In addition, it may be that the phase relation between the 
melatonin rhythm and the relevant SCN rhythm, e.g. the phase response curve to light, or the sleep-
propensity rhythm varies between individuals or conditions. 
 Kronauer and colleagues estimated the error of melatonin based phase assessments of the human 
circadian pacemaker in a detailed comparison of the variability of phase assessments using 
melatonin, cortisol and core body temperature (Klerman et al., 2002).  It was concluded that 
melatonin based methods were superior and that the standard deviation for melatonin based 
methods ranged from 14 to 21 min. This implies that within an individual, phase differences of more 
than approximately 30 minutes phase can be reliably assessed.  For a description of how accuracy 
and uncertainty of melatonin based phase assessments are affected by sampling frequency, analysis 
methods, populations studied and thresholds applied we refer to (Klerman et al., 2002) (Danilenko 
et al., 2014) (Lewy et al., 1999).
In its standard implementation, the main drawbacks of the DLMO are that: a) it requires special 
environmental conditions (dim light); and 2) it requires a time series of at least several hours of 
samples. The required sampling frequency and duration of the time series depends on any a priori 
knowledge about the approximate phase and on the required precision of the phase assessment. In 
many situations it can be assumed that melatonin will rise sometime in the evening hours or early 
night (a few hours prior to usual bedtime), whereas in other situations no such assumptions can be 
made (e.g. non-24 hour sleep-wake disorder, shift work, or jet lag), and a time series of 24 hours 
may be required to capture the DLMO. Whereas the DLMO is most commonly assessed under 
controlled laboratory conditions, protocols for the use of the DLMO in the home environment have 
been developed and validated in patient populations (Keijzer et al., 2011) (Pullman et al., 2012) 
(Burgess et al., 2016). 
Requirements/desirables for novel approaches to assess parameters of the SCN in humans  
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The main aim of novel approaches is to overcome the limitations of current approaches. At the same 
time, these novel approaches should meet the requirements outlined above, such as being robust 
against masking effects and be able to accurately reflect SCN phase.  Thus, novel phase markers 
should be evaluated against a gold standard phase marker for SCN, e.g. DLMO. The precision of the 
biomarker should meet the requirements of its application or use-case. Importantly, for many 
applications/use-cases the biomarker should assess the circadian parameter of interest with 
sufficient precision to quantify the parameter at the level of the individual, rather than the ‘group’ 
level.
How to quantify performance of a new marker? Performance of a new marker against a gold 
standard can be quantified in a variety of ways and different publications use different methods. 
Some of the metrics used are the error and its standard deviation, the absolute error and its 
standard deviation, the median error and its range, the fraction of samples with an error less than a 
particular threshold, the correlation between gold standard and novel marker, regression analysis of 
gold standard vs, novel method, and there are probably others. All these methods have their 
advantages and disadvantages and their validity depends on whether underlying assumptions about 
the distribution of the data, e.g. a normal distribution, are valid. An issue relevant for assessing 
errors of phase is that the circular nature of the data needs to be taken into account, e.g. a phase at 
23:59 and 00:02 h are very close. Another point to keep in mind is that a mean error may simply 
represent a systematic bias and can be corrected for and an absolute error is only useful if a 
systematic error (bias) cannot be corrected for.       
Novel approaches to assess circadian phase in humans
The novel approaches can be broadly classified into: a) circadian phase assessments based on one or 
a few samples of high dimensional (i.e. multivariate) material, like the transcriptome or 
metabolome; b) circadian phase assessments based on long-term passive sampling of behavioural, 
physiological, and/or environmental variables [Fig 3].
-Omics based assessment of circadian phase of central pacemaker using few samples 
High dimensional or multivariate refers to samples that contain a large number of variables or 
features, the constellation of which varies with circadian phase such that one timepoint suffices to 
assess any circadian phase. It has long been recognised that a single time point sample of high 
dimensional data may contain as much information about circadian phase as a timeseries of 
univariate data. The classical example is Linnaeus’ flower clock. Various species of flowers open at 
different times of day, and any given time of day is characterised by a constellation of open/closed 
flowers. It turns out that Linnaeus may never have actually planted a flower clock, and the accuracy 
of flower clocks that were planted by botanical gardens were affected by weather, latitude, and 
seasonal changes (https://en.wikipedia.org/wiki/Linnaeus%27s_flower_clock). The transcriptome, 
proteome, and metabolome are high dimensional data, and a considerable fraction of the thousands 
of variables in each of these -omics data sets has been shown to be rhythmic in human blood, 
adipose tissue, skin, and brain (Moller-Levet et al., 2013) (Christou et al., 2019) (Depner et al., 2018) 
(Ang et al., 2012) (Dallmann et al., 2012) (Wu et al., 2018).
A main problem in the development of biomarkers from high dimensional data is the selection of 
relevant features. Several approaches exist and may be subdivided in those that use a priori- 
knowledge, e.g. focus on RNAs from core circadian genes, or unbiased approaches (for a discussion 
see (Laing et al., 2017) (Laing et al., 2019b). When unbiased approaches are applied to, for example, 
the transcriptome, we are exposed to the curse of high dimensionality (e.g. ~ 20,000 transcripts) and 
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the resultant risk of ‘overfitting’.  When there are many more features than data points to be 
predicted or described it is always possible to find a set of features that will fit or describe a 
particular data set (like the training data set) but this set of features is much less likely to fit an  
independent data set (a test set). This problem of overfitting is addressed in machine learning 
approaches to feature selection and will not be discussed in detail here (Smith et al., 2014). 
A first single-time point sampling method for the assessment of circadian phase was developed in 
mice. This was an approach based on a prior knowledge since  it was based on more than 100 time-
indicating genes in the liver  (Ueda et al., 2004). Subsequently, a single-time point method for 
assessment of circadian phase in mice was developed based on plasma metabolites  (Minami et al., 
2009). The strengths of these single-time point methods in animals are that the methods were 
developed while controlling for effects of feeding, sex, age and the light-dark cycle, as well as that 
they were validated against gold standard SCN markers such as corticosterone. 
In humans, a first blood metabolite-based timetable method was developed based on data from 
three participants and validated in six participants using plasma cortisol and melatonin as gold 
standards  (Kasukawa et al., 2012). Data were collected under constant routine conditions at the 
beginning and end of a forced desynchrony protocol, with blood samples drawn every two hours 
during a 39-hour episode of wakefulness following sleep episodes which were located during the 
biological night. Using two blood samples taken 12 hours apart, the reported accuracy was 
approximately three hours. The set of metabolites used for the timetable construction consisted of 
58 rhythmic metabolites, a large fraction of which belonged to metabolism pathways of steroid 
hormones such as cortisol.
A first method to use the human blood transcriptome for the prediction of SCN phase was 
developed based on 329 mRNA samples from 26 participants to build the model, and a validation set 
of 349 mRNA samples from 27 participants (Laing et al., 2017). The blood samples were collected 
during a residential stay in a clinical research centre while participants were scheduled to a normal 
sleep-wake cycle, a misplaced sleep-wake cycle, or underwent a period of approximately 40 hours of 
sleep deprivation following a week of sufficient or insufficient sleep (Moller-Levet et al., 2013;  
Archer et al., 2014). These conditions to some extent mimic conditions like shift-work. Plasma 
melatonin data were used as a gold standard proxy for SCN phase. 
The development of a circadian biomarker based on these data was not based on an initial 
identification of rhythmic transcripts but used an unbiased ‘machine learning approach’ (partial least 
squares regression) to build a model. Transcripts were quantified by microarray technology using an 
Agilent platform. For the development of the model, data from all conditions were used, i.e. not just 
‘baseline’ but also conditions in which the circadian system was perturbed.  The rationale for using 
samples from various conditions for model development was that in real-world situations a sample 
may come from either normal or perturbed conditions and this will often be unknown. That the 
effects of sleep timing on putative transcriptome based biomarkers can be very substantial has been 
demonstrated in forced desynchrony experiments [Fig 2B].  A sample collected in a shift work setting 
may come from a shift worker in whom SCN phase may or may not have adapted to shift work and it 
will be unknown whether sleep is or is not displaced relative to SCN phase. 
This approach identified a set of 100 mRNA abundance features which was able to predict melatonin 
phase in the validation set with an accuracy (SD or error) of three hours based on one sample, and 
1h:40 min based on two samples taken 12 hours apart (82% of samples had an error less than two 
hours). The latter approach essentially is a within-subject normalisation procedure that improves 
performance of the method because it removes the large between-subject variation in the blood 
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transcriptome, i.e. the blood transcriptome is to some extent trait-like. The median error (which 
means that 50% of the samples have an error less than this number) was less than one hour for the 
differential model. Importantly, even though the model was developed from samples across a 
variety of sleep-wake conditions, the accuracy was still less when sleep occurred out of phase (See 
Fig 4). 
The unbiased approach used in Laing et al. (Laing et al., 2017) outperformed timetable methods and 
ZeitZeiger when applied to the same data set.
Comparing the features identified by each of these methods revealed that many of the features are 
not directly related to clock genes but many are related to glucocorticoid signalling pathways.   
Hughey and colleagues applied an algorithm (ZeitZeiger), in which a rhythmic spline is fitted to the 
data  (Hughey, 2017) to publicly available data sets collected at the University of Surrey and the 
University of Pennsylvania (Moller-Levet et al., 2013) (Archer et al., 2014) (Arnardottir et al., 2014). 
The algorithm builds a predictor for what is called ‘circadian time’. Importantly, in this analysis 
‘circadian time’ does not refer to the circadian phase of a sample based on melatonin phase in that 
individual, but to the time of the sample relative to sunrise or the melatonin phase averaged across 
individuals. The model was developed on data collected under baseline sleep-wake conditions and 
when applied to baseline data the absolute mean error was 2.1 hours. When the model was tested 
on conditions during which the sleep-wake cycle was displaced, the performance was worse, such 
that the variability in prediction error increased by 42% with a median absolute error greater than 
three hours.  Hughey and colleagues then developed strategies to improve prediction at the 
individual level by using more than one sample per participant, such that using two samples taken 8-
9 hours apart resulted in an average improvement in prediction of 0.43 hours to approximately 1.67 
hours. A strength of the ‘ZeitZeiger predictor’ is that it is based on a small set of 15 genes. In 
accordance with the results from Laing et al. (Laing et al., 2017), only a very few of these 15 genes 
were core clock genes. 
Braun et al. (Braun et al., 2018) developed a new algorithm using the University of Surrey and the 
University of Pennsylvania data sets, as well as a new data set consisting of RNAseq data obtained 
from healthy participants collected during unperturbed baseline conditions. The authors used a 2-
sample approach, and their method requires at least two samples which for optimal performance 
should be drawn 10-12 hours apart. Unfortunately, the authors did not use a circadian phase marker 
to validate their method but instead used external clock time (this limitation has been discussed 
previously (Laing et al., 2019a) (Braun et al., 2019)). They identified a set consisting of approximately 
40 genes, few of which were core clock genes. The reported median error based on two samples was 
two hours.
Whereas the Laing et al., Hughey et al., and Braun [CHANGE-18]  et al. approaches were based on 
whole blood, Wittenbrink and colleagues  (Wittenbrink et al., 2018) used monocytes as the source of 
their transcripts, assuming that rhythmicity would be more robust in this cell type. In addition, the 
authors argued that because microarray and RNAseq platforms are relatively inaccurate in detecting 
transcript levels, it may be beneficial to use other platforms for the implementation of circadian 
phase biomarker sets. Wittenbrink and colleagues took this into consideration when they developed 
a biomarker for circadian phase using a two-step process. In the first step, they used ZeitZeiger to 
identify a set of transcripts quantified by RNAseq. This predictor set was then implemented on a 
NanoString platform. Their initial search used samples collected in a group of healthy young men in a 
constant routine protocol, and their validation dataset was from a group of individuals with extreme 
chronotypes living in real-world conditions from whom samples were collected in the morning and 
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afternoon. In both cases, the gold standard proxy for circadian phase was salivary DLMO, which in 
the validation set varied between approximately 17:00 and 01:00 hours. The authors created 4 
predictors:  1-sample-12 genes; 1-sample-2 genes; 2-sample, 13-genes and 2-sample,2-genes.  In the 
validation set the median absolute error using the Nanostring platform was less than an hour across 
all predictors and timing of validation samples (morning, afternoon). The 1-sample 12-genes 
predictor had an absolute median error of 0.7 hours for a morning sample and 0.8 hours for 
afternoon sample. The performance of the two-sample predictors was similar to the one sample 
predictors (See Fig 4b). A weakness of this otherwise elegant study is that performance was not 
assessed under conditions in which sleep was displaced, such as in forced desynchrony, jet-lag, or 
shift work. Thus, we do not yet know to what extent the performance of this method will be affected 
by the masking effects of sleep, activity, posture, or feeding-fasting, which have been shown to be 
considerable.
Long term passive sampling-based assessment of circadian phase using activity, skin temperature, 
heart rate, light exposure, and other variables.
The desire to assess SCN phase based on passive monitoring of physiological and behavioural 
variables has a long history. Traditionally, these approaches used linear methods in which estimated 
masking effects were added or subtracted from the observed variables. However, the effects of 
masking differ across individuals and interact with circadian phase (that is, the masking effects are 
larger at some circadian phases than others), rendering simple addition/subtraction methods 
inadequate (Klerman et al., 1999). Recently, more sophisticated approaches in which multiple 
variables are recorded simultaneously and algorithms are used to predict melatonin phase have 
been developed using multiple regression or artificial neural network approaches. The various 
approaches differ primarily with respect to the included variables and required duration of data 
collection.
Skin temperature, light, and activity
Whereas core body temperature has long been considered a valuable marker of circadian phase it is 
cumbersome to measure by either rectal sensors or thermistor pills that are swallowed. Skin 
temperature can be measured in a less intrusive manner.  The circadian and sleep-wake and activity 
dependent regulation of skin temperature has been investigated extensively (Krauchi and Wirz-
Justice, 1994). Based on these findings skin temperature has been evaluated as a source of 
information about central circadian phase. Kolodyazhniy and colleagues published two approaches 
based on ambulatory skin temperature recordings (from six locations), (blue) light recordings from a 
sensor mounted on glasses, and motion (Kolodyazhniy et al., 2011;  Kolodyazhniy et al., 2012). 
Models were constructed using either multiple regression or artificial neural networks, and gold 
standard estimation of SCN phase was based on salivary melatonin collected under constant routine 
conditions. Participants were healthy but of various chronotypes, with a range of melatonin phases 
of slightly more than five hours. Performance of the algorithms was derived from leave-one-
participant-out cross-validation. The best model correlated well with melatonin phase (r=0.97) with 
a SD of the error of only 23 minutes. In one of the very few instances in which a model developed by 
one group was tested by another group, Stone et al. put this model to the test (Stone et al., 2019b). 
Importantly, in this study the model was tested not only in participants on a normal sleep-wake 
schedule but also in shift workers, and  the gold standard proxy for SCN phase was either DLMO or 
6-sulphatoxy melatonin. Whereas in this independent validation the model performed well under 
baseline conditions, the performance deteriorated dramatically for assessments in night shift 
workers such that the error was more than two hours in approximately half of the assessments (See 
Fig 4c]. This poor performance persisted even when the model was trained on night shift data. 
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Performance was even worse when the model was trained on non-shift-work data. The findings of 
this comprehensive study underscore the necessity to validate any method for circadian phase 
assessment in situations in which sleep and other masking effects are displaced, not only because 
these are more challenging conditions for most methods but because they represent situations in 
which circadian biomarkers will be used.
Combining a mathematical model for light with light exposure and activity data
Although in the studies of Kolodyazhniy et al. and Stone et al. light information was used to build a 
predictor algorithm, no specific model for how light affects the human circadian pacemaker was 
employed. Kronauer’s mathematical model for the effects of light (and activity) on the human 
circadian pacemaker  (Jewett et al., 1999;  St Hilaire et al., 2007) (Kronauer et al., 1982), which is 
based on the extensive laboratory studies by Czeisler and colleagues  (Duffy et al., 1996) (Boivin et 
al., 1996) (Czeisler et al., 1989) (Jewett et al., 1991) (Gronfier et al., 2004) (Chang et al., 2012), 
remains the only quantitative model to date (Duffy and Wright, 2005). It uses light, quantified as lux, 
as input and no provision for the spectral composition of light is available. The primary assumption 
underlying the use of Kronauer’s model to predict circadian phase is that light is the most powerful 
zeitgeber for the human SCN and that variations in timing and intensity of light exposure, which are 
in part driven by the timing of sleep and social constraints  (Skeldon et al., 2017), are the main 
determinants of variations in circadian phase. Determinants of phase of entrainment are well 
understood at a theoretical level  (Granada et al., 2013).  Phase of entrainment is determined by 
individual differences in intrinsic period (Wright et al., 2005)] and theoretically also by individual 
differences in light sensitivity. Woelders and colleagues used Kronauer’s model and reported that 
DLMO was associated with individual differences in light exposure, such that Light+Model explained 
52% of the variance (Woelders et al., 2017). When light data and Kronauer’s model were 
supplemented with activity data, DLMO could be predicted with a SD or error of 1.1 hours, i.e. 95% 
of the predictions had an error of 2.2 hours or less. It is noted that although the participants varied 
with respect to chronotype with a considerable range of measured DLMOs of 9.3 hours, they were 
all sleeping at their habitual bedtimes for the duration of the study. In a study of shift workers on 
either a diurnal or night schedule, Stone and colleagues used a similar approach, i.e. they either used 
a photic-only model or a combination of photic input to Kronauer’s model and activity (Stone et al., 
2019a). The proxy for SCN phase was 6-sulphatoxy melatonin. Performance on the diurnal schedule 
was comparable and even slightly better than in the Woelders et al. study. Although performance of 
the predictors deteriorated somewhat on the night schedule, performance was still rather good with 
a SD of 1.39 hours and 80% of predictions within two hours of the observed values (See Fig 4C). St. 
Hilaire and colleagues have also used individual light exposure data input to the Kronauer model to 
predict phase shifts in a simulated shift work study where salivary DLMO was assessed before and 
after a series of night shifts. They found that 85% of the model predictions were within 2 hours of 
the observed DLMO shifts (St. Hilaire & Duffy, personal communication).  
Heart rate  
Heart rate (HR) and heart rate variability (HRV) are under control of the autonomic nervous system, 
which in turn is under SCN control. The masking effect of activity and sleep on heart rate is 
considerable, but constant routine protocols have demonstrated an endogenous circadian 
component to heart rate  (Viola et al., 2002) (Vandewalle et al., 2007). In principle, this implies that 
ambulatory monitoring of heart rate may provide information on SCN phase provided that masking 
can be accounted for. Gil and colleagues investigated the potential of HR measures for circadian 
phase prediction using only 24 hours of data  (Gil et al., 2013) (Gil et al., 2014). The proxy for SCN 
phase was DLMO measured in 11 participants for model development and 19 participants for 
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performance testing. Participants slept at their habitual times and the range of chronotypes and 
DLMOs was relatively small, i.e. approximately three hours. The model was based on an 
autoregressive moving average with a linear combination of external inputs, e.g. heart rate or light. 
Using only heart rate as a predictor resulted in a SD of 56 minutes, similar to performance of a light 
input only model (with light transformed with a power function, as in Kronauer’s model). Combining 
heart rate and light resulted in performance with a SD of 39 minutes and adding activity did not 
improve performance significantly. Although performance of these models appears impressive, it 
should be noted that the range of DLMO was limited and this model has not been tested under 
conditions of displaced sleep.
New methods to assess intrinsic circadian period
Gold standard assessment of the intrinsic period of the SCN in sighted people is achieved through 
forced desynchrony of the sleep-wake cycle from the endogenous circadian rhythms by scheduling 
sleep-wake and the associated dim light-dark cycle to a non-circadian cycle length that is outside the 
range of entrainment  (Klerman et al., 1996) (Czeisler et al., 1999;  Duffy et al., 2011) (Lazar et al., 
2013). In totally blind individuals, intrinsic period can be assessed by repeated phase assessments of 
48-hour urinary 6-sulphatoxy melatonin while the participants are living in their habitual 
environment (Hack et al., 2003;  Lockley et al., 2015). These experiments have provided important 
insights into the role of interindividual variation in intrinsic period in entrainment. Several variants of 
the forced desynchrony protocol have been developed, and a consistent finding across studies is 
that that in participants without circadian rhythm sleep-wake disorders, the average period is about 
24.2 hours with a small standard deviation (Czeisler et al., 1999;  Duffy et al., 2011) (Micic et al., 
2016) (Eastman et al., 2017) (Hasan et al., 2012). Two alternative period assessment methods have 
emerged: a) in vitro recording of circadian rhythms in human cell cultures, in which cells are 
modified to express a luciferase gene under the control of the promoter of a ‘clock’ gene; and b) 
reducing the residual variance of light exposure and mathematical model-derived prediction of 
circadian phase (DLMO) by optimising the period parameter of Kronauer’s model at the level of the 
individual. The latter method has yielded a realistic population average and SD for circadian period, 
but individual estimates have not been validated against gold standard assessments. Furthermore,  
the period estimates were based on only one circadian phase assessment per participant, and the 
optimisation procedure may therefore not reflect intrinsic period but rather the period which best 
predicts this single circadian phase (Woelders et al., 2017).
For the in vitro circadian period assessment methods, a number of validated studies are available in 
both blind and sighted individuals. However, in these studies the average in vitro period is longer 
than that derived from forced desynchrony studies, and systematically longer than that derived in 
the same individuals by melatonin (Pagani et al., 2010;  Hasan et al., 2012). In fact, the correlation 
between the in vitro periods and the periods as assessed by urinary 6-sulphatoxy melatonin (in blind 
individuals) or by plasma melatonin in forced desynchrony studies in sighted people are weak and 
sometimes not even significant. It thus appears that the current in vitro assessments will not be able 
to accurately assess intrinsic period at the level of the individual. 
New methods to assess intrinsic circadian amplitude/circadian disruption
Changes in the amplitude of overt rhythms such as activity or body temperature are often observed, 
in for example ageing, and it is also often tacitly assumed that these changes reflect changes in the 
amplitude of the endogenous circadian components of these variables. As we have previously 
argued, protocols such as the constant routine are needed to ascertain this (Duffy and Dijk, 2002) 
[Duffy and Dijk].However, in general, the concept of circadian amplitude is not well-defined and a 
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simple gold standard measure for circadian amplitude has not been agreed upon.  For example, 
there is substantial variation in melatonin amplitude between individuals, and little evidence that 
those individual differences reflect differences in SCN amplitude.  Studies in which a constant 
routine has been carried out before and after the circadian system has been perturbed have 
demonstrated that changes in the amplitudes of cortisol, melatonin, and core body temperature in 
response to an intervention are generally correlated [Jewett et al. 1991 [(Dijk et al., 2012). This 
suggests that the amplitudes of these measures may reflect the amplitude of oscillations within the 
SCN, and that it may be possible to develop a metric for circadian amplitude. 
New approaches to assess endogenous circadian amplitude are based on multivariate approaches. 
These methods may not necessarily aim to assess the amplitude of the SCN but may be targeted at 
assessment of peripheral oscillators. In fact, these methods may not aim to assess the simple 
construct of amplitude but instead metrics that reflect the robustness or ‘normality’ of circadian 
processes. The assumption is that under normal conditions diurnal oscillations in a particular organ 
or tissue are characterised by a typical progression of expression levels of genes (a tissue specific 
temporal program), and in particular genes that are at the core of the generation of circadian 
rhythmicity. Shilts and colleagues designed a method to quantify ‘circadian disruption’ by computing 
a metric called ‘clock correlation distance’ (CCD) which is based on the co-expression patterns of 12 
’clock genes’  (Shilts et al., 2018). A larger CCD indicates less normal, or less robust rhythmicity. The 
method was developed on samples from various mouse tissues but then applied to samples from 
human blood, skin, brain and in vitro cell cultures. The robustness of circadian rhythmicity as 
detected by this method varied between blood, skin, brain and in vitro cell cultures. The method 
does not require samples to be labelled with time of day, works best if the entire circadian cycle is 
covered but can perform reasonably well if only part (e.g. one third) of the circadian cycle is covered. 
For the method to produce reliable results in humans it requires approximately 30 samples, and the 
method cannot be applied to a single sample. One application for this method is in cancer research 
and it was indeed shown that this method detects disruption of circadian rhythmicity in tumours.
Vlachou and co-workers also aimed to develop a method to quantify circadian disruption as well as 
circadian time with intended application in oncology [BioRxiv doi: 
http://dx.doi.org/10.1101/622050]. Their method, called ‘time teller’ is based on 10-15 genes, 
requires only one sample, and is designed to be used to both assess circadian phase as well as 
circadian ‘dysfunction’. As mentioned, these methods to assess circadian disruption are built on the 
notion that during a normal circadian cycle, at any point in the cycle there is a specific constellation 
of rhythmic genes being expressed. This assumption can be used to tell time from a single sample 
but also can be used to detect disruption of circadian organisation. Obviously, these methods are 
very much focussed on the local circadian organisation of the tissue from which the sample was 
obtained. Circadian disruption in the periphery does not necessarily imply circadian disruption in the 
central circadian clock. For example, severe disruption of circadian organisation of the 
transcriptome, including expression of core clock genes, has been observed in the whole blood 
transcriptome when sleep was displaced to the daytime while at the same time the phase and 
amplitude of the plasma melatonin rhythm were similar to when sleep occurred at night (Archer et 
al., 2014).
These observations highlight both the potential of using multivariate data in the periphery to detect 
circadian disruption or quantify ‘amplitude’ while at the same time emphasizing the need for careful 
validation and interpretation of these data. For the assessment of the physiological patency of a 
local tissue, the cause of the disruption of temporal programs may not be that important. However, 
in any multi-oscillator system, local rhythmicity and its disruption may sometimes reflect disruption 
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of local clocks, disruption of circadian rhythmicity downstream from those local clocks, or disruption 
of central clocks imposing rhythmicity on those local tissues.
Concluding remarks
Wearables and -omics data combined with machine learning and mathematical modelling hold great 
promise for the development of novel methods to quantify circadian processes in humans. Optimal 
choice of variables to be collected by wearables, the -omics to be used in ‘one sample’ methods, or 
the source of samples, i.e. blood, skin, saliva, remain to be established. This choice of variable(s) will 
be influenced by the purpose of the biomarker (See Fig 1,2).  Until now, much emphasis has been on 
the development of ‘sophisticated’ algorithms without clearly stating the purpose of the biomarker. 
Little effort has been devoted to comparison of these biomarkers to gold standards, validating them 
in realistic protocols, or defining the required accuracy across use cases. A variety of performance 
measures have been used in different studies, and reaching a consensus on the performance metrics 
of biomarkers will facilitate comparison across methods.
It will be useful to evaluate these new methods within a framework that is based on concepts 
developed in circadian rhythm research together with concepts from the field of biomarker 
development.  Organisations such as the FDA and NIH together with Industry partners have provided 
guidelines for the evidence needed for biomarker qualification and a description of the workflow 
and decision processes in biomarker development (Leptak et al., 2017). Some of the key concepts 
that can be applied to circadian biomarkers are ‘context of use’ which relates to ‘what question does 
the biomarker address’, the ‘biological rationale for use of biomarker’, ‘independent data sets for 
qualification’ and ‘comparison to current standard’.  
Circadian concepts such as diurnal vs. circadian rhythmicity, masked vs. endogenous circadian 
rhythms will remain useful when evaluating new markers for circadian processes. Likewise, 
biomarker concepts such as robustness, reliability, sensitivity, and specificity should be formalized 
for our field and applied to any novel method designed for quantifying circadian rhythms. It may be 
unrealistic to expect that a particular biomarker for, for example circadian phase, is universally 
robust, i.e. can be applied in a wide range of situation and populations and it may be that ‘situation’  
‘population’ or ‘diagnosis’ specific approaches can be developed. However, in practise the precise 
situation, population or diagnosis will be often unknown. Therefore, for these novel, be it universal 
or specific, biomarkers to be useful they should be validated in controlled laboratory settings where 
the rest-activity schedules of participants are manipulated, tested in men and women of all ages, 
tested in large groups of normal individuals in “real life” situations, and tested in patient 
populations, particularly those patient populations in which these methods will be applied. 
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Figure legends
Fig 1. A biomarker for which rhythm and what generates this rhythm? 
Modified from (Bollinger and Schibler, 2014). Structure of the human circadian timing system. 
Molecular clocks and circadian rhythms are present in the brain including the SCN-based oscillator 
and periphery.  A circadian biomarker may provide information about the rhythms in the SCN or in 
peripheral tissues and organs. Rhythms in organs and tissues are influenced by external rhythmic 
signals, SCN driven signals, local circadian oscillators and behavioural rhythms such as sleep or 
eating. A biological sample will contain many features (transcripts, proteins, metabolites). These 
various features will be influenced by SCN input, the local circadian oscillator and behaviour. The 
selection of the final feature set for the biomarker will depend on the purpose of the biomarker, e.g. 
assessing SCN phase or phase of tissue specific circadian oscillator. In many cases, the tissue or organ 
of interest will not be accessible and the features will be extracted from for example blood, which 
makes the identification of robust biomarkers even more challenging,  
Fig 2. Effects of sleep-wake cycle and light exposure on rhythmic variables
Panels A Daily rhythm of core body temperature is altered when sleep occurs in phase (at night) vs. 
out of phase. Recalculated from  (Dijk and Czeisler, 1995). Panel B Rhythms of plasma melatonin and 
cortisol are not much affected by sleeping in phase (during the night) or out of phase (during the 
day) [data from (Archer et al., 2014). Panel C Frequency distribution of the acrohases of rhythmic 
transcripts when sleeping  in phase (blue) and out of phase.  From: (Archer et al., 2014). Panel D 
Individual level dose-response curves for melatonin suppression and light levels. Blue High sensitivity 
individual; Red: Low sensitivity individual. From (Phillips et al., 2019).      
Fig 3. Univariate multiple sampling vs multivariate single sample
A) A multivariate biomarker will require one or two samples separated by several hours, and by 
containing information about multiple rhythmic features the relative level of each of those features 
can classify the overall circadian timing (Laing et al., 2017). B) With a univariate biomarker, a time 
series of points assessing a single feature is collected. Depending on the variability of the feature, 
“noise” from periodic behaviors or physiologic changes and/or environmental changes, may 
influence any one data point or cycle, but multiple cycles of data will provide an accurate 
assessment of the underlying rhythmic process.
Fig 4. Examples of predictors of circadian melatonin phase and impact of sleeping ‘out of phase’ on 
accuracy of biomarker prediction
Panel A Prediction of plasma melatonin phase from two samples taken 12 hours apart across the 
circadian cycle during wakefulness (green symbols),  nocturnal sleep (light blue symbols) and 
misplaced sleep (dark blue circles). From (Laing et al., 2017): 
Panel B Prediction of salivary melatonin phase from one sample taken in the afternoon during 
wakefulness from extreme morning and evening types living on their habitual sleep-wake schedule. 
Men: triangles; Women circles. Size of circles indicates age of participants. From  (Wittenbrink et al., 
2018).
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Panel C Prediction of urinary 6sulfatoxy melatonin phase from recordings activity, light exposure and 
a mathematical model for the effects of light in participants living on a ‘nocturnal’ schedule. From  
(Stone et al., 2019a)
Panel D Absolute error and its standard deviation of various biomarkers when tested on participants 
sleeping during the night (in phase) or during the day (out of phase) in either the laboratory or in a 
shift work situation. In all cases the biomarker-predicted phase was compared to a gold standard 
phase marker (plasma melatonin for the transcriptome predictors (Laing et al., 2017)) and urinary 6-
sulfatoxy melatonin for the neural network (Stone et al., 2019b) and light model (Stone et al., 
2019a). In all cases, accuracy was worse for the ‘out of phase’ condition.
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